For over a decade, we’ve been driven by our commitment to Reimagine Possible for patients. Starting with Greg Verdine’s founding vision to challenge convention and push the boundaries of innovation, we have combined best-in-class chemistry, human genetic insights, and novel

Introducing WVE-008, a potential first-in-class, disease modifying therapy for the treatment of PNPLA3 I148M liver disease, which builds on the clinical translation of our RNA editing capability. Watch our recent Research Day presentation to learn more: https://t.co/XwaVJ62lbX

Today we announced our 3Q 2025 earnings update. We’re incredibly encouraged by the progress we’ve made across our INLIGHT trial for obesity and our RestorAATion-2 trial for AATD. Looking forward, we have a tremendous opportunity to build on our strong momentum as we continue to

We’re attending #TLM25 to present new preclinical data (poster #4025). Visit us at booth #948 to learn more about our RNA editing programs. @AASLDtweets #AASLD

We are incredibly excited to be observing potent, durable dose-dependent Activin E reductions with a single dose of WVE-007 in the first three cohorts of our INLIGHT clinical trial in obesity. With multiple catalysts for this program ahead, here’s what to expect. You can also

We’re in Atlanta at @ObesityWeek 2025! Join us Thursday at 2:30 p.m. at Poster-710 to learn more about the therapeutic potential of WVE-007 for obesity. Read the press release here: https://t.co/guSv6EaHR0 #ObesityWeek #OW2025

On Monday, November 10, we will present our 3Q earnings update. Register and listen to the webcast here: https://t.co/1tkkKLRm2q $WVE

At our annual Research Day, we shared a positive target engagement update from the INLIGHT clinical trial of WVE-007, our GalNAc INHBE-siRNA designed to reduce Activin E, inducing fat loss while preserving muscle. We’re excited about the potential impact this program could have

Join us for our annual Research Day tomorrow, Wednesday 10/28 at 10 a.m. ET. Register here: https://t.co/oddJzUfHdl

We’re headed to #HDCongress2025 and look forward to connecting with the HD community. Stop by our table to learn more about SELECT-HD, our clinical trial for WVE-003, our first-in-class, allele-selective oligonucleotide for the treatment of HD. @HuntingtonSG $WVE

This week our team will be in Vienna attending #WMS2025. On Saturday at 7:45 a.m. CET, we are presenting our 48-week results from our FORWARD-53 study of WVE-N531 to the @WorldMuscleSoc and community. Visit booth 19 to say hello and learn more about our work in #Duchenne. $WVE

We are thrilled to welcome @PaulBolno to Invivyd's Board of Directors. Dr. Bolno is the President and CEO of the innovative biotech company, Wave Life Sciences, and he is an expert in developing new medicines to keep people healthy. Please read the press release for more

Our management team will be participating in multiple investor conferences in the upcoming months: ➡️ Bernstein Healthcare Forum ➡️ @Stifel Virtual Cardiometabolic Forum ➡️ @ChardanCM Genetic Medicines Conference Links to webcasts below. $WVE

We’ve been collaborating with the #Duchenne community for more than ten years and today on World Duchenne Day, we join them to raise awareness and inspire action that change the lives of families impacted by #DMD. To the Duchenne community, thank you for a decade of partnership.

This morning we shared a positive update from the ongoing RestorAATion-2 trial of WVE-006 in AATD, where we achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases and the first-ever demonstration of

Today we announce a positive update from our ongoing RestorAATion-2 trial of WVE-006 in alpha-1 antitrypsin deficiency. Read the press release: https://t.co/a1t6D7VB6e Join us at 8:30 AM ET for an investor webcast: https://t.co/0Z94zq54CE $WVE

At Wave, every day is #RNADay. For over a decade, we’ve been advancing the #RNA field, building the industry’s leading multimodal platform, PRISM, for developing RNA medicines. From editing to silencing to splicing RNA, our best-in-class chemistry is designed to unlock the broad

Today we announced our 2Q 2025 earnings update, including that we remain on track to share clinical data sets this year for the RestorAATion-2 trial for WVE-006 in #AATD, as well as INLIGHT for WVE-007 in #obesity. $WVE

On Wednesday, July 30, we will present our 1Q earnings update. Click below to register and listen to the webcast. $WVE

Wave’s success is built on our team’s drive, passion, and collaboration. Anthony Murabito, our VP of IT and Chief of Data Security, talks to @The_Swan_Group's Biotech Bytes podcast about how we think about talent management, the potential of AI, and more.